Natco Pharma Limited has announced the launch of its generic Semaglutide injection in India, available from March 21, 2026. The product, offered in multi-dose vials, is priced at a starting MRP of ₹1,290, making it the most affordable option in the market.
The company received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market the generic version of Semaglutide. This medication is indicated for adults with type 2 diabetes mellitus who have not achieved sufficient control through diet and exercise alone.
Natco’s Semaglutide injection will be available in vial strengths of 2mg/1.5ml, 4mg/3ml, and 8mg/3ml under the brand names SEMANAT and SEMAFULL. The vials are priced at ₹1,290 per month for the 2mg/1.5ml and 4mg/3ml strengths, and ₹1,750 for the 8mg/3ml strength.
In addition to vials, Natco plans to launch a pen device version in April 2026, with prices set at ₹4,000, ₹4,200, and ₹4,500 per month for the respective strengths. The company is the first to offer Semaglutide in a vial dosage form, which is approximately 70% cheaper than the pen device and 90% cheaper than the innovator’s brand.
Natco’s introduction of this cost-effective GLP-1 therapy aims to enhance patient accessibility and support long-term compliance for those requiring diabetes management.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).